Figure 2.
Platelet engraftment, median time of platelet engraftment, platelet recovery, and numbers of required platelet transfusion in the rhTPO group (n = 59) and the control group (n = 60). (A) Sixty-day cumulative incidence of platelet ≥20 × 109/L between the rhTPO group and control group. (B) One hundred twenty–day cumulative incidence of platelet ≥50 × 109/L between the rhTPO group and control group. (C) Median time of platelet ≥20 × 109/L in the rhTPO group and control group. (D) Numbers of required platelet transfusion in the rhTPO group and control group.

Platelet engraftment, median time of platelet engraftment, platelet recovery, and numbers of required platelet transfusion in the rhTPO group (n = 59) and the control group (n = 60). (A) Sixty-day cumulative incidence of platelet ≥20 × 109/L between the rhTPO group and control group. (B) One hundred twenty–day cumulative incidence of platelet ≥50 × 109/L between the rhTPO group and control group. (C) Median time of platelet ≥20 × 109/L in the rhTPO group and control group. (D) Numbers of required platelet transfusion in the rhTPO group and control group.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal